Global Contraceptives Industry

Find Industry reports, Company profiles
ReportLinker and Market Statistics

>> Get this Report Now by email!

Global Contraceptives Industry
Published on October 2010

Report Summary

This report analyzes the worldwide markets for Contraceptives in US$ Million by the following product segments: Oral Contraceptives,
Condoms, Implants/ Injections, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan,
Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2007 through
2015. A seven-year historic analysis is also provided for these markets. The report profiles 164 companies including many key and
niche players such as Ansell Limited, Bayer Schering Pharma AG, Church & Dwight Co. Inc., Conceptus, Inc., Condomi Health
International GmbH, Female Health Company, Fuji Latex Co Ltd., Johnson & Johnson, Ortho-McNeil-Janssen Pharmaceutical Inc.,
Merck & Co., Inc., Okamoto Industries, Inc., SSL International PLC, Teva Pharmaceutical Industries Limited, Warner Chilcott, Pfizer
Inc., and Wyeth Corporation. Market data and analytics are derived from primary and secondary research. Company profiles are
mostly extracted from URL research and reported select online sources.

Table of Content

CONTRACEPTIVES MCP-2528
A GLOBAL STRATEGIC BUSINESS REPORT

CONTENTS

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Data Interpretation & Reporting Level 2
Quantitative Techniques & Analytics 3
Product Definitions and Scope of Study 3
Oral Contraceptives 3
Condoms 4
Implants/Injections 4
Other Contraceptives 4

2. INDUSTRY OVERVIEW 5
A Primer 5
Table 1: World Contraceptive Use (2007): Percentage Share of
Women in the Age Group of 15 to 49 Years Utilizing
Contraceptives - Breakdown by Region and Type of
Contraceptive Method 6

Global Contraceptives Industry Page 1/21


Table 2: Global Female Contraceptive Market (2007):
Percentage Market Share Breakdown of Leading Players - Bayer,
Johnson & Johnson, Schering-Plough, Barr Pharmaceuticals,
Wyeth Laboratories, and Others (includes corresponding
Graph/Chart) 6

Table 3: Global Contraceptive Market: Percentage Share
Breakdown of Leading Brands by Number of New Prescriptions
(NRX) for the Month of January & June 2008 and January 2009
(includes corresponding Graph/Chart) 7
Impact of Recession: An Unequivocal Review 7
Cooling Economy Induces Changes in Childbearing Trends 7
Recession Adds Fuel to Cost/Affordability Challenge 8
Rising Preference for Surgical Family Planning Procedures 8
Outlook 8
Other Trends & Issues 9
Increasing Awareness Over STDs to Create Additional Demand
for Condoms 9
HIV Prevalence and Incidence Statistics 9
Table 4: Global Prevalence of HIV Infection by Region (2007
& 2008) in Millions (includes corresponding Graph/Chart) 10
Table 5: HIV Prevalence in Select Countries (2007) 11
Multifunctional Modern Contraceptives Make a Foray 12
Skin Sprays: A Novel Way of Contraception 12
Extensive Distribution Drives growth of Contraceptive Products 12
Public Health Organizations Spur Condoms Use 13
USAID Worldwide Shipments of Condoms and Other Contraceptives 13
Table 6: USAID Shipments of Condom and Other Contraceptives
Worldwide (2008): Percentage Value Share Breakdown by Region
-Africa, Asia/Near East, Latin America/the Caribbean,
Europe/Eurasia, and Middle East (includes corresponding
Graph/Chart) 14
Advertising for Contraceptives Acquires A Whole New Dimension 14
Manufacturers & Retailers Work in Sync to Accelerate Sales 14
Innovation Keeps the Fire Burning for the Condoms Market 15
Generic & Biosimilar Contraceptive Products Gain Ground 15
Generics Manufacturers 15
OTC Hormonal Contraceptives - An Attractive Market 16
R&D Companies & Generic Manufacturers - Developing Countries 16
Commercial Success of R&D Brands Sustain Developmental
Programs in Developing Countries 17
Challenges Facing Generic Contraceptive Products Manufacturers 17

3. PRODUCT OVERVIEW 18
Types of Contraception 18
The Contraceptive Timeline 18
Table 7: World Contraceptive Prevalence (2005): Percentage
Use of Select Contraception Methods In Less Developed and
Developed Regions - Traditional Method, Pill, IUD, Condom,
Implant/Injectables, Male Sterilization, Female



Sterilization (includes corresponding Graph/Chart) 19
Classification 19
By Function 19
Barrier Contraceptives 19
Characteristic Features of Barrier Methods 20
Hormonal Contraceptives 20
Prescription Contraceptives 20
Oral Contraceptives 20
Overview of Oral Contraceptives - Benefits vs. Risks 21
Usage Levels of OCs in Worldwide Scenario 21
Table 8: Percentage of Women in the age group 15-49 using
contraception across select regions and countries for the
years 2005 and 2006 22
Traditional and Modern 22
Reversible and Permanent 23
Birth Control Methods and their Use in Major Regions
Worldwide 23
Contraception - Levels of Effectiveness 24
Effectiveness Index of Contraceptive Measures 24
Unmet Need for Contraception 26
Segmental Analysis 26
A. Condoms 26
Overview 26
Categories 26
Latex Condoms 26
Non-Latex Condoms 26
Skin Condoms 27
Polyurethane (PU) Condoms 27
Table 9: Leading Product Types in the US Condoms Market
(2005) - Percentage Share Breakdown for Latex,
Synthetic/Polyurethane and Natural (includes corresponding
Graph/Chart) 27
Comparison Between Polyurethane & Latex Condoms 27
Male Condom - Effectiveness of Protection Against STDs 28
Myths & Facts 28
Selection & Effective Use of Condoms 28
Condoms in the War Against AIDS 28
Highlights 29
Growth Factors 29
Factors Hindering Wide Spread Use of Condoms 30
Measures Aimed at Increasing Usage 30
Female Condoms 30
Who are the Main Users' 31
Reality - An Effective Female Condom 31
B. Oral Contraceptives (OCs)/Pills 31
A Peep into the Past 32
Synthetic Oral Contraceptives 32
Characteristic Features of Oral Contraceptives (OCs) 32
Top Brands/Manufacturers of Oral Contraceptive
Formulations Containing Levonorgestrel 0.15 MG/ Ethinyl



Estradiol 30 mcg 33
Table 10: Worldwide Hormonal Contraceptive Players
(2005)- Market Share Breakdown by Leading Players:
Schering AG, J&J, Barr, Wyeth, Watson, Akzo Nobel, and
Others (includes corresponding Graph/Chart) 34
Bayer Schering Pharma's 'Yasmin': A Resounding Brand Worldwide 34
Table 11: Sales of Bayer Schering Pharma AG's Yasmin, and
Yaz for the Years 2007 and 2009 (In Euro Millions) 35
Advantages of Using Ocs 35
Effects of Long-Term Use of OCs 35
Use of OCs/Pills - Myths & Facts 36
Oral Contraceptives - Challenges & Strategies to Overcome
Problems 36
Factors Associated with Failure of OCs/Pills 37
Health Conditions to be Addressed when Using OCs 37
Understanding Risks Associated with Use of OCs 37
Cardiovascular Disease - A Major Side Effect of OCs 38
Intake of OCs Result in High Blood Pressure 38
Smoking Intensifies Respiratory Problems in Pill Users 38
Complications Arising by Use of OCs Directly Related to Age 38
Relation Between OC and Cancer 38
Depression Linked to Use of OCs 39
OCs Increases Osteoporosis Risk at Later Stage 39
OCs May Reduce Sex Drive 39
Effects of Pill on Childbearing Capacity 39
Visiting a Doctor - Highly Recommended in Case of Warning
Symptoms 40
Emergency Contraception (EC) - A New Face of OCs 40
Role of ECPs 40
Effectiveness of ECP 41
Different Types of EC Products 41
Mini Pills 41
RU486 - the French Abortion Pill 42
Top Brands/Manufacturers of Emergency Contraceptive Pills
Containing Levonorgestrel 0.75 mg 42
Top Brands/Manufacturers of Emergency Contraceptive Pills
Containing Levonorgestrel 0.25mg and Ethinyl Estradiol
50mcg 43
Availability of Hormonal Contraceptives as OTC Drugs 43
C. Injectable Contraceptives 43
Depo-Provera 43
Characteristic Features of Injectable Contraceptives 44
Injectables - Challenges & Strategies to Overcome Problems 44
Top Brands & Manufacturers of Two & Three Month Injectable
Contraceptive Formulations Containing Depot
Medroxyprogesterone Acetate (DMPA), and Norethisterone
Enanthate 45
Top Brands & Manufacturers of Monthly Injectable
Contraceptive Formulations Containing (Norethisterone
Enanthate 50 mg and Estradiol Valerate 5 mg), (Dihydroxy



Progesterone Acetophenide 75 mg and Estradiol Enanthate
5 mg), (Medroxyprogesterone Acetate 25 mg and Estradiol
Cypionate 5 mg), (Algeston acetophenide 150 mg and
Estradiol Enanthate 10 mg), and Hydroxiprogesterone
Caproate 250 mg 46
D. Intrauterine Devices (IUDs)/Implants 47
Product Categories 47
CopperT 380A (ParaGard) 47
Progesterone T (or Progestasert) 47
Characteristic Features 48
Benefits 48
Side Effects 48
Challenges & Strategies to Overcome Problems 49
Table 12: IUD Users Worldwide (2005): Percentage Breakdown
by Select Geographic Country/Region Geographic
Country/Region IUD Users (includes corresponding
Graph/Chart) 49
Long-term Reversible Contraceptive Implants 50
Products 50
Norplant 50
Implanon 50
Mirena 50
Characteristic Features of Implantable Contraceptives 51
Challenges & Strategies to Overcome Problems 51
E. Spermicides 52
Product Categories 52
Benefits 52
Drawbacks 52
Contraceptive Foam 52
Delfen Contraceptive Foam 52
Contraceptive Cream or Jelly 53
Encare Ovals 53
F. Diaphragms 53
G. Withdrawal & Douching 53
H. Sterilization 54
Tubal Ligation 54
Reasons Behind Adoption 55
Risk of Complications 55
Types 55
Abdominal Procedures 55
Laparoscopy 55
Mini-Laparotomy 56
Laparotomy 56
Vaginal Procedures 56
Culdoscopy 56
Colpotomy 56
Hysterectomy - A High Risk Surgery 56
Selective Tubal Occlusion Procedure (STOP) 56
Vasectomy 57
Method of Working 57



Reasons Behind Adoption 57
Risk of Complications 58
I. Other Contraceptive Methods 58
Contraceptive Sponges 58
Today Sponge 58
Characteristic Features of Today Sponge 59
Table 13: Efficiency Rates of Today Sponge Based on Usage
for 12-Month Period (includes corresponding Graph/Chart) 60
Allendale Pharmaceuticals 60
Protectaid Sponge 60
Characteristic Features of Protectaid Sponge 61
Cervical Caps 61
Pros and Cons of the Device 61
Vaginal Contraceptive Film (VCF) 62
Contraceptive Vaccine 62
Ortho Evra Weekly Contraceptive Patch 62
NuvaRing Monthly Vaginal Ring 63

4. RESEARCH AND DEVELOPMENT 64
Oral Contraceptive Minimizes Premenstrual Syndrome Symptoms as
per New Study 64
Cause of Infertility - Not Associated with IUDs 65
Presence of Estrogen in OCs Offers Protection from Colorectal
Cancer 65
Hormonal Contraceptive Usage & Risk Associated with Certain STDs 65
Use of Third Generation Ocs Increases Risk of Blood Clots 65
High Risk of Deep Vein Thrombosis with Cyproterone- Containing
OCs 66

5. ROLE OF UNITED NATIONS IN PROMOTING USE OF CONTRACEPTIVES 67
Female Condoms Reach New Heights with Aid from UNAIDS 67
Donor Support for Contraceptive Commodity 67
Table 14: Total Cost of Contraceptives and Condoms:
2000-2010E (In US$ Million) (includes corresponding
Graph/Chart) 67
Unmet Need 68
Table 15: Donor Support by Region: 2004 (includes
corresponding Graph/Chart) 68
Table 16: Contraceptive Donor Support for STI/HIV Prevention
by Agency: 1997-2004 (US$ 000) 68
Donor Support by Contraceptive Method 69
Table 17: Donor Support by Contraceptive Method: 2000-2004
(In Thousand Units) (includes corresponding Graph/Chart) 69

Table 18: Donor Support for Contraceptive Method by Agency:
2000-2004 (In US$ Mill) (includes corresponding Graph/Chart) 69
Donor Support by Top Ten Countries 70
Table 19: Major Donor Support Recipient Countries: 2004 (In
US$ Million) (includes corresponding Graph/Chart) 70



Table 20: Donor Support for Condoms and Other Contraceptive
Commodities: 1997-2004 (In terms of %) (includes
Donor Funding For Male Condoms 71
Table 21: Donor Funding For Male Condoms: 2000- 2004

Table 22: Donor Funding For Male Condoms by Region: 2004

Table 23: Number of Male Condoms Supplied by Donors:
Region-Wise Breakup for year 2004 72

Table 24: Donor Support for Condoms (1995-2004): Number of
Condoms by Donor - USAID, UNFPA, BMZ/KfW, DFID, EU, DKT,
PSI, IPPF, MSI, Netherlands, SIDA, and Japan (In Thousand
Units) (includes corresponding Graph/Chart) 74

Table 25: Donor Funding for Condoms (1995-2004): Number of
Condoms by Donor - USAID, UNFPA, BMZ/KfW, DFID, EU, DKT,
PSI, IPPF, MSI, Netherlands, SIDA, and Japan (In US$ 000)

Table 26: Total Number of Female Condoms in Private and
Public Sectors: Region-wise Split from Years 1997 through
2004 (includes corresponding Graph/Chart) 76

Table 27: Percentage of Couples Using Condoms for Family
Planning (2005) by Region 76
Use of Modern Contraceptives Grows in Developing Regions 78
Table 28: Estimated Numbers of Contraceptive Users in
Developing Nations: 2000-2015 (In Millions) (includes

Table 29: Comparative Study of Modern Contraception Methods
in Developing Regions (including India & China) and
Developing Regions (excluding India & China) - Percentage of
Married Women Using Oral Contraceptives, Female
Sterilization, and Intrauterine Devices (IUDs): Recent Past
Data for 2000 (includes corresponding Graph/Chart) 80
Difference in Usage of Oral contraceptives in Developed and
Developing World 80
Table 30: Oral Contraceptives Usage by Married and Sexually
Active Unmarried Women (Aged 15-49 years) in Developed
Regions including North America, Eastern Europe & Central
Asia, and Australia & New Zealand: Recent Past Data for 2000 80

Table 31: Oral Contraceptives Usage by Married and Sexually
Active Unmarried Women (Aged 15-49 years) in Developing
Regions including Asia, Near East & North Africa,



Sub-Saharan Africa, Pacific Rim, and Latin America &
Caribbean: Recent Past Data for 2000 81
Prevalence of Contraceptive Methods 81
Table 32: Increase in Contraceptive Usage by 2005 -
Percentage Share Growth by Asia, Latin America and Africa

Table 33: Worldwide Contraceptives Market: Estimated Number
of Users (2015 & 2025) - Asia, Latin America and Africa

Table 34: Worldwide Contraceptive Market: Prevalence Amongst
Women (2000-2025) - Percentage Share by Asia, Latin America
and Africa (includes corresponding Graph/Chart) 82
United Nations Population Fund (UNFPA) 82
UNFPA Gets Aid from Britain to Help Developing World 83
Rise in Cost of Providing Contraceptives 84
Future Trends Worldwide 84

6. NEW PRODUCT INTRODUCTIONS/ INNOVATIONS 85
HLL Lifecare to Launch Pan Flavoured Condoms 85
Glenmark Generics Receives USFDA Approval for Norethindrone
Tablets 85
HLL Lifecare to Introduce Moods in Australian Markets 85
Organon Releases Contraceptive NuvaRing 85
HRA Pharma Unveils ellaOne 85
Bayer Introduces Qlaira New Oral Contraceptive 86
Durex Introduces Avanti Bare' 86
Teva to Introduce Tri-Lo Sprintec 86
Teva Announces Launch of Topiramate Tablets 86
Duramed Releases LoSEASONIQUE 86
Uganda Health Marketing Group Rolls Out NewFem, A New
Contraceptive Pill 87
TTK LIG to Unveil Durex Jeans Condoms 87
Teva Pharmaceutical Industries Receives Approval for Plan B
One-Step Emergency Contraceptive 87
Cupid Limited to Unveil Cost-effective Female Condoms 87
Bayer Schering Pharma Launches QlairaÂ® 88
Watson Laboratories Secures USFDA Approval for Plan B OTC
Generics 88
Organon Launches Vaginal Contraceptive Ring 88
Bayer Schering Pharma Rolls Out Oral Contraceptive 88
Hindustan Latex Introduces New Contraceptive Pill 89
FHI and HLL Launch Aastha Condom 89
NATCO Launches World-Class Oral Contraceptive 89
Bayer Plans Launch of Mirena in Japan 89

7. RECENT INDUSTRY ACTIVITY 90
FHC Bags Order to Supply 3.5 Million FC2 Female Condoms for
2010 World Cup in South Africa 90



SSL Acquires Majority Stake in BLBV 90
Columbia Laboratories Inks Definitive Agreement with Watson
Pharmaceuticals 90
Piramal Healthcare Signs Definitive Agreement with Cipla 91
Watson Pharmaceuticals to Market HRA Pharma's Emergency
Contraceptive 91
Lupin to Establish Three New Production Facilities 91
Pfizer to Purchase Wyeth 91
Ansell Healthcare Signs Agreement with NYC Department of
Health and Mental Hygiene 92
Teva Pharmaceutical Industries' Yaz Receives FDA Approval 92
Teva Pharmaceutical Industries' Yaz Receives Marketing
Approval from FDA 92
Watson Pharmaceuticals, Warner Chilcott Collaborate for Femring 92
Watson Pharmaceuticals Inks Agreement with Warner Chilcott for
WC3026 93
Merck Merges with Schering-Plough 93
Vystar Inks Agreement with Centrotrade Minerals and Metals and
Centrotrade Deutschland 93
Mayer Laboratories Signs Agreement with Alvogen Group 94
Hypermarcas Acquires Inal 94
Sosei Inks Distribution Agreement with ASKA Pharmaceuticals 94
Sanofi-Aventis to Construct Plant in Brazil 94
Durex Chinese Plant Starts Production 94
Patheon Expands Toronto Plant 95
Female Health Co Receives FDA Approval for Cheaper Female Condom 95
Mylan and Famy Care Sign Strategic Alliance for Exploring the
US Oral Contraceptive Market 95
Starpharma Holdings Signs Full License Agreement with SSL
International Plc 96
SSL International to TakeOver Crest Condom Brand 96
Teva Pharmaceutical Industries Acquires Barr Pharmaceuticals 96
Duramed Pharmaceuticals' LoSEASONIQUE® Receives FDA Approval 97
Bayer Schering Pharma's Qlaira® Receives Decentralized Drug
Approval 97
Bayer and Barr Pharmaceuticals Sign Agreements 97
Female Health's FC2 Receives FDA Approval 98
Faes Farma Signs Agreement with Gruenenthal 98
'Female Health' Bags Order in Papua New Guinea 98
Mylan Enters into Alliance with Famy Care 98
Bayer Schering Pharma to Launch YAZ Oral Contraceptive 99
Wuhan Humanwell Hi-Tech Industry to Expand Pharmaceutical
Business 99
Watson Laboratories Receives FDA Approval 99
Organon Licenses Spray Technology from Acrux 99
BioSante Initiates Phase II Trials of Oral Contraceptives 100
YAZ® Receives FDA Approval for New Indication 100
Paladin Labs Receives Approval to Market SEASONALE® 100
ENJUVIA(TM) (Synthetic Conjugated Estrogens, B) Receives Two
FDA Approvals (USA) 100



Conceptus Receives FDA Approval for Third-Generation Essure ®
Procedure 101
Wyeth Receives FDA Approval for Lybrel ' 101
NuvaRing® Completes European Authorization in 13 Countries 101
HLL Expands Promotion of Female Condom 101
ChrysCapital Gains Minority Stake in Mankind Pharma 102
7 Chemicals Inks Deal with Ferring Pharmaceuticals 102
Synova Acquires Allendale Pharmaceuticals and Global Rights to
Today Sponge 102
Ansell Pockets Blowtex 102
Bayer Merges with Berlex to Establish Bayer HealthCare
Pharmaceuticals 102
UNFPA Releases Pacific-Design Condoms 103
Wyeth Completes Acquisition of Wyeth K.K. Japan 103
Conceptus, Inc. to Acquire Conceptus SAS 103
Warner Chilcott Company Enters into a Supply Agreement with
Watson Pharma 103
SSL International Fully Acquires Qingdao London Durex Co Ltd 104
Bayer HealthCare Takes Over Marketing/Distribution Network of
Pharmonyx Ltd. 104

8. FOCUS ON SELECT PLAYERS 105
Ansell Limited (Australia) 105
Bayer Schering Pharma AG (Germany) 105
Church & Dwight Co., Inc. (US) 105
Conceptus Inc (US) 106
Condomi Health International GmbH (Germany) 106
Female Health Company (US) 106
Fuji Latex Co Ltd (Japan) 106
Johnson & Johnson (US) 107
Ortho-McNeil-Janssen Pharmaceutical Inc (US) 107
Merck & Co., Inc (USA) 108
Okamoto Industries Inc (Japan) 108
SSL International PLC (UK) 108
Teva Pharmaceutical Industries Limited (Israel) 108
Warner Chilcott (US) 109
Pfizer Inc (USA) 109
Wyeth Corporation (US) 109

9. GLOBAL MARKET PERSPECTIVE 111
Table 35: World Recent Past, Current & Future Analysis for
Contraceptives by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Latin America and Rest
of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2007 through 2015 (includes

Table 36: World Historic Review for Contraceptives by
Geographic Region - US, Canada, Japan, Europe, Asia- Pacific
(excluding Japan), Latin America and Rest of World Markets



Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2006 (includes corresponding
Graph/Chart) 112

Table 37: World 11-Year Perspective for Contraceptives by
Geographic Region- Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Latin America and Rest of World Markets for Years 2005, 2010 &

Oral Contraceptives by Geographic Region - US, Canada, Japan,

Table 39: World Historic Review for Oral Contraceptives by
Graph/Chart) 115

Table 40: World 11-Year Perspective for Oral Contraceptives by

Condoms by Geographic Region- US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Latin America and Rest of
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2007 through 2015 (includes

Table 42: World Historic Review for Condoms by Geographic
Region - US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), Latin America and Rest of World Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2006 (includes corresponding Graph/Chart) 118

Table 43: World 11-Year Perspective for Condoms by Geographic
Region- Percentage Breakdown of Dollar Sales for US, Canada,
Japan, Europe, Asia-Pacific (excluding Japan), Latin America
and Rest of World Markets for Years 2005, 2010 & 2015




Implants/Injections by Geographic Region- US, Canada, Japan,

Table 45: World Historic Review for Implants/Injections by
Graph/Chart) 121

Table 46: World 11-Year Perspective for Implants/Injections by

Other Contraceptives by Geographic Region- US, Canada, Japan,

Table 48: World Historic Review for Other Contraceptives by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
Graph/Chart) 124

Table 49: World 11-Year Perspective for Other Contraceptives
by Geographic Region- Percentage Breakdown of Dollar Sales for

10. THE UNITED STATES 126
A.Market Analysis 126
Outlook 126
Restraints 126
Are Women's Reproductive Rights Getting Axed on the New
Health Care Bill' 126
Major Market Trends 127
Changing Consumer Demographics 127
Relentless Promotional Programs Drive Home the Point 128
Use of Intimacy Products on the Rise 128
Generics Ransack the Branded Market 128



Condoms - A 'Fun, Inviting and Pleasurable' Way to Healthy
Life and Lifestyle 129
Market Share Statistics 129
Table 50: US Market for Male Contraceptives: Percentage
Breakdown of Retail Dollar Sales of Key Players for the
Year Ended January 2007 (includes corresponding
Graph/Chart) 129

Table 51: US Market for Male Contraceptives: Breakdown of
Retail Unit Sales of Key Players for the Year Ended January
2007 (In 000 Units) 130

Table 52: US Market for Female Contraceptives: Percentage
Breakdown of Retail Dollar Sales of Key Players for the
Year Ended January 2007 (includes corresponding
Graph/Chart) 130

Breakdown of Retail Unit Sales of Key Players for the Year
Ended January 2007 (includes corresponding Graph/Chart) 130

Breakdown of Dollar Sales of Leading Brands for the Year
Ended March 2005 (includes corresponding Graph/Chart) 131

Table 55: US Condoms Market: Percentage Breakdown of Dollar
Sales by Product Type for the Year Ended January 2006
Noticeable Shift in Retail Marketing Techniques 131
Rising Use of Condoms Amongst Teenagers 132
Changing Attitudes and Perceptions Drive Market Sales 132
Pill Continues to be One of the Most Popular Forms of
Contraception 133
Oral Contraceptives and its Shades of Grey 133
Marketing Efforts Aimed at Influencing Female College Students 133
Condoms Continuing Canter 134
Drug Stores Remain the Choice for Contraceptive Needs 134
Trade Class Statistics 134
Oral Contraceptives - Unanimously the Choice of American Women 135
Table 56: Contraceptive Features Preferred by Women in US

Table 57: US Market for New Prescription (NRx) Oral
Contraceptive (Estrogen/ Progestogen-based) Drugs (2006):
Percentage Market Share Breakdown of Leading Players

Table 58: US Market for Prescription (Rx) Oral
Contraceptives: Percentage Market Share Breakdown of
Leading Players for the Year 2007 (includes corresponding



Graph/Chart) 136

Table 59: US Prescription Contraceptives Market: Percentage
Market Share Breakdown for Select Product Categories for
the Years 2007 (includes corresponding Graph/Chart) 136

Table 60: US Market for Prescription Extended Cycle Oral
Contraceptives: Percentage Market Share Breakdown for
Leading Brands for the Years 2007 (includes corresponding
Graph/Chart) 137
Health Facts 137
Rising Use of Oral Contraceptives 137
Abortion Control Drugs & Methods 138
Medical Abortion 138
a. Mifepristone - A Medical Breakthrough 138
b. Methotrexate 138
Expanding the Use & Availability of EC Drugs 138
Pharmacies Sell ECPs 139
Demographics 139
Facts and Figures 139
Sales of Contraceptives (Male & Female) - Family Planning
Category 139
Insurance Coverage for Contraceptives Still in Contest 140
Key Player 140
Watson Pharmaceuticals 140
B.Market Analytics 141
Table 61: US Recent Past, Current & Future Analysis for
Contraceptives by Product Segment- Oral Contraceptives,
Condoms, Implants/Injections and Others Markets
Graph/Chart) 141

Table 62: US Historic Review for Contraceptives by Product
Segment - Oral Contraceptives, Condoms, Implants/Injections
and Others Markets Segments Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2000 through

Table 63: US 11-Year Perspective for Contraceptives by
Product Segment - Percentage Breakdown of Dollar Sales for
Oral Contraceptives, Condoms, Implants/ Injections and
Others Markets for 2005, 2010 & 2015 (includes corresponding
Graph/Chart) 143

11. CANADA 144
Scenario 144
Outlook 144
Condoms Market 144



Immucon Obtains US Patent for Male Contraceptive Technology 145
Table 64: Canadian Recent Past, Current & Future Analysis
for Contraceptives by Product Segment- Oral Contraceptives,
Graph/Chart) 145

Table 65: Canada Historic Review for Contraceptives by
Product Segment - Oral Contraceptives, Condoms,
Implants/Injections and Others Markets Segments
Graph/Chart) 146

Table 66: Canadian 11-Year Perspective for Contraceptives by
Product Segment - Percentage Breakdown of Dollar Sales Oral
Contraceptives, Condoms, Implants/Injections and Others
Markets for 2005, 2010 & 2015 (includes corresponding
Graph/Chart) 147

12. JAPAN 148
Outlook 148
Market for Oral Contraceptives Yet to Take Off 148
Innovation Expected to Drive Sales 148
Major Issues and Trends 149
Domestic Products Dominate the Market 149
Health Care Institutions Remain Main Distribution Channels 149
Market Issues 149
Compulsory Labeling of Contraceptives 149
Late Approval for Use of OCs in Japan 149
Factors Hindering Widespread Use of OCs 150
Condoms Market 150
Key Player 150
Sagami Rubber Industries Co., Ltd 150
Table 67: Japanese Recent Past, Current & Future Analysis
for Contraceptives by Product Segment- Oral Contraceptives,
Graph/Chart) 151

Table 68: Japanese Historic Review for Contraceptives by



Graph/Chart) 152

Table 69: Japanese 11-Year Perspective for Contraceptives by
Oral Contraceptives, Condoms, Implants/Injections and Others
Graph/Chart) 153

13. EUROPE 154
Outlook 154
Condoms Market 154
Table 70: European Recent Past, Current & Future Analysis
for Contraceptives by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets
Graph/Chart) 155

Table 71: European Historic Review for Contraceptives by
Contraceptives by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets
Graph/Chart) 156

Table 72: European 11-Year Perspective for Contraceptives by
Geographic Region - Percentage Breakdown of Dollar Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2005, 2010 & 2015 (includes corresponding
Graph/Chart) 157

Table 73: European Recent Past, Current & Future Analysis
for Contraceptives by Product Segment - Oral Contraceptives,
Graph/Chart) 158

Table 74: European Historic Review for Contraceptives by
Graph/Chart) 159

Table 75: European 11-Year Perspective for Contraceptives by



Graph/Chart) 160

13a. FRANCE 161
Outlook 161
Condoms Market 161
Table 76: French Recent Past, Current & Future Analysis for
Graph/Chart) 162

Table 77: French Historic Review for Contraceptives by
Graph/Chart) 163

Table 78: French 11-Year Perspective for Contraceptives by
Graph/Chart) 164

13b. GERMANY 165
Outlook 165
German Women Record Highest Usage Rate of Contraceptive Pill 165
Condoms Market 165
Table 79: Leading Players in the German Condoms Market
(2005) - Percentage Share Breakdown by Sales Revenues -
Sico, Vizit and Others-A Historic Review (includes
Table 80: German Recent Past, Current & Future Analysis for
Graph/Chart) 166

Table 81: German Historic Review for Contraceptives by
Product Segment - Oral Contraceptives, Condoms, Implants/
Injections and Others Markets Segments Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2006 (includes corresponding Graph/Chart) 167



Table 82: German 11-Year Perspective for Contraceptives by
Graph/Chart) 168

13c. ITALY 169
Outlook 169
Table 83: Italian Recent Past, Current & Future Analysis for
Graph/Chart) 169

Table 84: Italian Historic Review for Contraceptives by
Graph/Chart) 170

Table 85: Italian 11-Year Perspective for Contraceptives by
Graph/Chart) 171

13d. THE UNITED KINGDOM 172
Outlook 172
Overview 172
Changing Societal Trends 172
Innovations: Need of the Hour 173
Table 86: Contraception Market in the United Kingdom:
Percentage of Women Aged 16-49 Years Using Select Methods
of Contraception As of the Year 2005-06 (includes
Availability of Contraceptives 174
Contraceptive Injections 174
Emergency Contraception (EC) 174
Barrier Contraceptives 174
Major Trends and Issues 174
Hormone Based Products Overtake Barrier Products 174
Condoms Still Find Immense Favor in Britain 174
Value of Condoms Declines Even as Volume Sales Increases 175
Table 87: Leading Players in the UK Condoms Market (2005)



- Percentage Share Breakdown by Sales Revenues - Durex,
Contex and Others - A Historic Review (includes
Role of Pharmacies in Improving Availability of Condoms and
EC Drugs 175
Regulatory Environment 175
CEN Standards 175
Advertising and Promotion 176
Hormone Based Contraceptives Restricted by Legislation 176
Table 88: UK Recent Past, Current & Future Analysis for
Contraceptives by Product Segment - Oral Contraceptives,
Graph/Chart) 176

Table 89: UK Historic Review for Contraceptives by Product
Segment - Oral Contraceptives, Condoms, Implants/Injections
and Others Markets Segments Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2000 through

Table 90: UK 11-Year Perspective for Contraceptives by
Oral Contraceptives, Condoms, Implants/Injections and Others
Graph/Chart) 178

13e. SPAIN 179
Current & Future Analysis 179
Outlook 179
Table 91: Spanish Recent Past, Current & Future Analysis for
Graph/Chart) 180

Table 92: Spanish Historic Review for Contraceptives by
Product Segment - Oral Contraceptives, Condom



Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.

Global Contraceptives Industry

Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 4 500.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________



Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Global Contraceptives Industry

Recommended

Recommended

More Related Content

What's hot

What's hot (18)

Similar to Global Contraceptives Industry

Similar to Global Contraceptives Industry (20)

More from ReportLinker.com

More from ReportLinker.com (20)

Global Contraceptives Industry